Equities Analysts Set Expectations for CTXR FY2024 Earnings

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Free Report) - Stock analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Citius Pharmaceuticals in a research note issued on Tuesday, November 12th. HC Wainwright analyst V. Bernardino now anticipates that the company will earn ($0.26) per share for the year, down from their prior forecast of ($0.21). HC Wainwright has a "Buy" rating and a $4.00 price target on the stock. The consensus estimate for Citius Pharmaceuticals' current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Citius Pharmaceuticals' Q4 2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.18) EPS.

Citius Pharmaceuticals (NASDAQ:CTXR - Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01).

Citius Pharmaceuticals Stock Performance

CTXR stock traded down $0.03 during midday trading on Thursday, reaching $0.36. The company's stock had a trading volume of 4,885,079 shares, compared to its average volume of 1,456,414. Citius Pharmaceuticals has a 1 year low of $0.25 and a 1 year high of $1.07. The firm has a market capitalization of $64.37 million, a price-to-earnings ratio of -1.61 and a beta of 1.66. The stock has a fifty day simple moving average of $0.44 and a two-hundred day simple moving average of $0.60.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC bought a new position in Citius Pharmaceuticals in the 2nd quarter worth about $5,928,000. BNP Paribas Financial Markets raised its position in Citius Pharmaceuticals by 88.5% during the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company's stock valued at $62,000 after purchasing an additional 32,686 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Citius Pharmaceuticals by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company's stock worth $6,286,000 after buying an additional 104,889 shares during the period. Arkadios Wealth Advisors grew its position in shares of Citius Pharmaceuticals by 50.0% during the 2nd quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company's stock worth $88,000 after buying an additional 50,000 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Citius Pharmaceuticals during the second quarter valued at $69,000. Hedge funds and other institutional investors own 16.88% of the company's stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.